Table 1 Patient characteristics by receipt of ALND in SJTUBCDB.
Characteristics | All N(%) | Non-ALND Group | ALND Group | P value |
|---|---|---|---|---|
Year of diagnose | ||||
2013–2016 | 35 (29.7) | 16 (34.8) | 19 (26.4) | 0.443 |
2017–2020 | 83 (70.3) | 30 (65.2) | 53 (73.6) | |
Age (years) | ||||
< 49 | 59 (50.0) | 28 (60.9) | 31 (43.1) | 0.168 |
50–64 | 47 (39.8) | 16 (34.8) | 31 (43.1) | |
> 65 | 12(10.2) | 2(4.3) | 10(13.9) | |
Menopausal status | ||||
Pre | 68 (57.6) | 32 (69.6) | 36 (50.0) | 0.057 |
Post | 50 (42.4) | 14 (30.4) | 36 (50.0) | |
Histology | ||||
IDC | 99 (83.9) | 33 (71.7) | 66 (91.7) | 0.013 |
ILC | 1 (0.8) | 1 (2.2) | 0 (0.0) | |
Others | 18 (15.3) | 12 (26.1) | 6 (8.3) | |
Grade | ||||
I | 12 (10.2) | 5 (10.9) | 7 (9.7) | 0.764 |
II | 68 (57.6) | 28 (60.9) | 40 (55.6) | |
III | 38 (32.2) | 13 (28.3) | 25 (34.7) | |
T stage | ||||
T1 | 65 (55.1) | 30 (65.2) | 35 (48.6) | 0.114 |
T2 | 53 (44.9) | 16 (34.8) | 37 (51.4) | |
Ki67 | ||||
≤ 20 | 47 (39.8) | 17 (37.0) | 30 (41.7) | 0.751 |
>20 | 71 (60.2) | 29 (63.0) | 42 (58.3) | |
Subtype | ||||
HR+/HER2- | 87 (73.8) | 29 (63.1) | 58 (80.6) | 0.123 |
HR+/HER2+ | 13 (11.0) | 6 (13.0) | 7 (9.7) | |
HR-/HER2+ | 13 (11.0) | 7 (15.2) | 6 (8.3) | |
HR-/HER2- | 5 (4.2) | 4 (8.7) | 1 (1.4) | |
LVI | ||||
No | 99 (83.9) | 40 (87.0) | 59 (81.9) | 0.641 |
Yes | 19 (16.1) | 6 (13.0) | 13 (18.1) | |
Number of sentinel-nodes removed | ||||
1 | 7 (5.9) | 1 (2.2) | 6 (8.3) | 0.677 |
2 | 15 (12.7) | 7 (15.2) | 8 (11.1) | |
3 | 37 (31.4) | 13 (28.3) | 24 (33.3) | |
4 | 23 (19.5) | 9 (19.6) | 14 (19.4) | |
5 | 14 (11.9) | 7 (15.2) | 7 (9.7) | |
≥ 6 | 22 (18.6) | 9 (19.6) | 13 (18.1) | |
Number of metastatic sentinel-nodes | ||||
1 | 108 (91.5) | 43 (93.5) | 65 (90.3) | 0.787 |
2 | 10 (8.5) | 3 (6.5) | 7 (9.7) | |
Chemotherapy | ||||
No | 18 (15.3) | 7 (15.2) | 11 (15.3) | 1 |
Yes | 100 (84.7) | 39 (84.8) | 61 (84.7) | |
Radiotherapy | ||||
No | 104 (88.1) | 46 (100.0) | 58 (80.6) | 0.004 |
Yes | 14 (11.9) | 0 (0.0) | 14 (19.4) | |
Endocrine therapy | ||||
No | 28 (23.7) | 15 (32.6) | 13 (18.1) | 0.112 |
Yes | 90 (76.3) | 31 (67.4) | 59 (81.9) | |
Targeted therapy | ||||
No | 96 (81.4) | 38 (82.6) | 58 (80.6) | 0.971 |
Yes | 22 (18.6) | 8 (17.4) | 14 (19.4) | |
